The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
((3R)-1-(8-(1-(4-Chloro-1H-pyrazol-1-yl)ethyl)-9H-purin-2-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone ID: ALA4280459
Chembl Id: CHEMBL4280459
PubChem CID: 145980134
Max Phase: Preclinical
Molecular Formula: C20H25ClN8O
Molecular Weight: 428.93
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CC(c1nc2cnc(N3CCC[C@@H](C(=O)N4CCCC4)C3)nc2[nH]1)n1cc(Cl)cn1
Standard InChI: InChI=1S/C20H25ClN8O/c1-13(29-12-15(21)9-23-29)17-24-16-10-22-20(26-18(16)25-17)28-8-4-5-14(11-28)19(30)27-6-2-3-7-27/h9-10,12-14H,2-8,11H2,1H3,(H,22,24,25,26)/t13?,14-/m1/s1
Standard InChI Key: VKZMFONLOPNWIE-ARLHGKGLSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 428.93Molecular Weight (Monoisotopic): 428.1840AlogP: 2.65#Rotatable Bonds: 4Polar Surface Area: 95.83Molecular Species: NEUTRALHBA: 7HBD: 1#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 10.13CX Basic pKa: 3.59CX LogP: 2.16CX LogD: 2.16Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.69Np Likeness Score: -1.76
References 1. Futatsugi K, Huard K, Kung DW, Pettersen JC, Flynn DA, Gosset JR, Aspnes GE, Barnes RJ, Cabral S, Dowling MS, Fernando DP, Goosen TC, Gorczyca WP, Hepworth D, Herr M, Lavergne S, Li Q, Niosi M, Orr STM, Pardo ID, Perez SM, Purkal J, Schmahai TJ, Shirai N, Shoieb AM, Zhou J, Goodwin B.. (2017) Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile., 8 (4): [PMID:30108796 ] [10.1039/C6MD00564K ] 2. Futatsugi K, Huard K, Kung DW, Pettersen JC, Flynn DA, Gosset JR, Aspnes GE, Barnes RJ, Cabral S, Dowling MS, Fernando DP, Goosen TC, Gorczyca WP, Hepworth D, Herr M, Lavergne S, Li Q, Niosi M, Orr STM, Pardo ID, Perez SM, Purkal J, Schmahai TJ, Shirai N, Shoieb AM, Zhou J, Goodwin B.. (2017) Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile., 8 (4): [PMID:30108796 ] [10.1039/C6MD00564K ]